Events for November 18, 2025
9th Antifibrotic Drug Development Summit
2025 has seen a wave of positive anti-fibrosis advances. From Agomab’s Phase 2a results in fibrostenosing Crohn’s, Boehringer’s Phase 3 IPF data, Stanford’s TGF-β work in cardiovascular fibrosis, to over $3B in deals from Lilly, GSK, and others, it’s clear the antifibrotic drug development landscape is undergoing a seismic shift. That’s why this year’s Antifibrotic […]
Model-Informed Drug Development Summit
With the release of the draft ICH M15 guidelines and the FDA’s move to phase out animal testing, regulatory change is accelerating, solidifying Model-Informed Drug Development (MIDD) as a critical, non-negotiable tool in the drug development process. The Model-Informed Drug Development Summit is the first and only industry-focused, 3-day strategic meeting dedicated to exploring how MIDD is […]
3rd LNP Characterization & Analytical Development Summit
3rd LNP Characterization & Analytical Development Summit De-Risk Regulatory Submissions Through Smarter LNP Characterization Curated in collaboration with leading analytical scientists and key LNP stakeholders, the 3rd LNP Characterization & Analytical Development Summit returns with new data, fresh insights, and an expanded speaker lineup. As the definitive forum for LNP analytics and characterization, this summit […]
7th Myeloid-Directed Therapies Summit
The Only Industry-Dedicated Summit for Advancing Myeloid Cell Therapies in Oncology, Inflammation and Beyond... Uniting leading experts from pharma, biotech, and academia, the 7th Myeloid-Directed Therapies Summit is the definitive event for anyone developing macrophage- and neutrophil-targeted therapies. As the field pushes beyond T-cells, this forum dives into myeloid reprogramming, cell state heterogeneity, and translational […]
9th Dermatology Drug Development Summit
The 9th Dermatology Drug Development Summit is the definitive industry-led forum bringing together a driven community of experts pioneering innovative drug discovery and clinical strategies to improve long-term outcomes for patients with immuno-inflammatory disease. With disease heterogeneity and biomarker discovery fueling a new wave of research, and clinical pipelines facing intensifying competition, the need to develop differentiated, […]
